Crossmark

EGFRvIII TandAbs are specific and highly potent drug candidates for the treatment of solid tumors

Crossref DOI link: https://doi.org/10.1186/2051-1426-3-S2-P219

Published Online: 2015-11-04

Published Print: 2015-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Ellwanger, Kristina

Reusch, Uwe

Fucek, Ivica

Weichel, Michael

Gantke, Thorsten

Knackmuss, Stefan

Molkenthin, Vera

Marschner, Jens-Peter

Treder, Martin
More Information

Article History

First Online: 4 November 2015